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1. Introduction 
Pulmonary hypertension is the manifestation of a disorder of the pulmonary vascular bed, 
which results in obstruction of pulmonary blood flow. Although many different causes 
exist, hypertension in the pulmonary circulation is the result of increased vascular 
resistance, increased vascular bed flow, or both. The signs and symptoms of pulmonary 
hypertension are nonspecific and subtle. Left untreated, patients will experience 
progressive symptoms of dyspnea and right heart failure culminating in a markedly 
curtailed survival [Gaine, 2000]. Idiopathic pulmonary arterial hypertension is a relatively 
rare disease of unknown cause [Lloyd et al, 1995]; however, in the perioperative arena the 
majority of patients encountered with pulmonary hypertension have acquired it 
secondary to a cardiac or a pulmonary disease process. Left sided ventricular or atrial 
disease and left sided valvular heart disease are common causes of pulmonary 
hypertension. Both of these conditions elevate left atrial pressure and passively increase 
pulmonary venous pressure, pulmonary artery pressure (PAP), and pulmonary vascular 
resistance (PVR). Multiple respiratory diseases lead to the development of pulmonary 
hypertension via a hypoxia-induced vasoconstriction [Phillips et al, 1999]. Regardless of 
causation, all pathways lead to an altered vascular endothelium and smooth muscle 
function through cellular remodeling [MacLean, 1999; Tuder et al, 2001]. This results in 
increased vascular contractility or lack of vascular relaxation in response to various 
endogenous vasodilator substances. Detailed discussion of the pathology, 
pathophysiology, evaluation and treatment are provided elsewhere in this text and via 
consensus statements from the American College of Cardiology/American Heart 
Association. [McLaughlin et al, 2009] 
From a clinical anesthesia standpoint, although mild pulmonary hypertension rarely 
impacts anesthetic management, severe or moderate pulmonary hypertension can lead to 
acute right heart failure (RHF) and cardiogenic shock. The perioperative management of 
patients with pulmonary hypertension varies depending upon the pathological features 
present, functional clinical classification (Table 1), hemodynamics, and success of current 
medical therapy. This chapter will provided an overview of the pre-operative evaluation, 
intraoperative considerations, management strategies and postoperative considerations. 
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Table 1. Functional Assessment of the patient with pulmonary hypertension. 
2. Preoperative evaluation and preparation 
Surgery for patients with pulmonary hypertension is associated with significant morbidity 
and mortality regardless of the anesthetic technique utilized [Krowka et al, 2004; Martin et 
al, 2002; Ramakrishna et al, 2005; Roberts & Keast 1990; Tan et al 2001; Weiss & Atanassoff, 
1993]. For example, patients with Eisenmenger’s syndrome undergoing cesarean section 
have had mortality reported as high as 70% [Kahn, 1993]. Although there is not an 
overabundance of literature regarding the development of postoperative pulmonary 
complications following noncardiac surgery, the few studies that do exist demonstrate the 
risk associated with procedures. Therefore, medical optimization is critical. During 
perioperative risk assessment, one should take into account the type of surgery, the patient’s 
functional status, the severity of the pulmonary hypertension, the function of the right 
ventricle and any co-morbidities. Superficial procedures and non-orthopedic procedures 
will be associated with less hemodynamic and sympathetic nervous system perturbations 
than more invasive procedures. Orthopedic procedures with bony involvement can be quite 
stimulating for the patient and will increase the risk of increases in PVR and RV failure. 
Thoracic surgery is associated with changes in intrathoracic pressures, lung volumes and 
oxygenation, which may cause acute increases in PVR and decreased RV function [Ross AF 
et al., 2010]. Laparoscopic surgery requires pneumoperitoneum which may be poorly 
tolerated because it can decrease preload and increase afterload. Procedures associated with 
rapid blood loss may be poorly tolerated. 
2.1 History and physical exam 
Preoperative evaluation should include a thorough history and physical examination with 
special attention paid to signs and symptoms of right ventricular dysfunction. Symptoms are 
typically nonspecific with the most frequent being progressive dyspnea. The signs present 
depend on disease severity with dyspnea at rest, low cardiac output with metabolic acidosis, 
hypoxemia, evidence of right heart failure (large V wave on jugular vein, peripheral edema, 
hepatomegaly), and syncope being useful indicators [Blaise et al, 2003]. Laboratory studies 
should be directed according to the procedure that the patient is undergoing and the 
medication profile of the patient. Tests that should be strongly considered include 
electrocardiography, chest radiographs, echocardiography, and possibly right heart 
catheterization. In addition, depending on severity of the pulmonary hypertension, the 
following studies may also be useful, especially in the initial workup or depending on causes: 
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pulmonary function testing, arterial blood gas analysis, ventilation/perfusion scanning, 
pulmonary angiography, spiral computed tomography, serologic testing, and liver function 
testing. The ECG may demonstrate signs of right ventricular hypertrophy, such as tall right 
precordial R waves, right axis deviation and right ventricular strain [Nauser & Stites, 2001], 
but ECG changes alone cannot determine disease severity or prognosis [Ahearn et al, 2002; 
Bossone et al, 2002]. The chest radiograph may show evidence of right ventricular hypertrophy 
(decreased retrosternal space) or prominent pulmonary vasculature.  
Among the myriad of available tests, echocardiography is the screening method of choice. 
Echocardiography may be useful to show right ventricular hypertrophy and to estimate 
pulmonary arterial pressure [Blaise et al, 2003]. Right heart catheterization is the gold 
standard for measuring pulmonary arterial pressures, however. Evidence of significant right 
ventricular dysfunction should prompt reevaluation of the need for surgery [Pearl, 2005]. 
All attempts to lower pulmonary arterial pressure should be done prior to surgery. 
Treatment options include oxygen, bronchodilators, vasodilators and inotropes. In addition 
to the careful evaluation of the patient’s current therapeutic regimen for pulmonary 
hypertension, all other medications should be reviewed for possible interactions with others 
that may need to be instituted while under anesthesia. Likewise, it is important to maintain 
the patient’s current therapeutic regimen as withdrawal of medications can lead to rebound 
pulmonary hypertension and RV dysfunction. Although medications such as inhaled 
prostacyclin (epoprostenol or Flolan®) are associated with impaired platelet aggregation, 
they have not been implicated in clinically significant bleeding. Due to the short half-life of 
this medication, epoprostenol should not be stopped at any time in the perioperative period. 
The anesthesiologist must ensure preoperative maximization of the patient’s therapeutic 
options has been accomplished and coordinate, if needed, a strategy for continuance of 
chronic pulmonary hypertension therapy perioperatively.  
2.2 Perioperative care team coordination 
The major physiologic consideration for patients with pulmonary hypertension is the effect of 
increased PVR on right ventricular function. The induction and maintenance of general 
anesthesia coupled with positive pressure ventilation can cause dramatic hemodynamic effects 
in the patient with pulmonary arterial hypertension. These patients have an increased risk of 
developing significant cardiac dysfunction and have an increased risk of perioperative 
cardiovascular complications [Carmosino et al, 2007; Subramaniam & Yared, 2007]. Because of 
this, after preoperative data have been collected and reviewed, it is imperative that the 
anesthesiologist understands the causes and pathophysiology of the patient’s disease so that a 
therapeutic perioperative regimen and anesthetic plan can be established. Although major 
advancements in treatment have prolonged survival and improved these patients’ quality of 
life, no current therapy cures this disease. Depending on the severity and chronicity of the 
disease, the patient may or may not respond to vasodilator therapy. Owing to the complexity 
of most pulmonary hypertension treatment protocols, preoperative evaluation and 
optimization by the patient’s primary pulmonary physician is desirable whenever possible. 
The perioperative medical treatment of this disease frequently involves a multidisciplinary 
(respiratory therapists, pharmacists, nurses, pulmonologist, anesthesiologist, surgeon, etc…) 
approach and, depending upon the level of specialization of your institution, coordination of 
these efforts could take considerable ‘lead’ time. Most patients with PHTN will be categorized 
as American Society of Anesthesiologists (ASA) Physical Status 4 (Table 2). 
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ASA Physical Status 1 A patient with mild systemic disease 
ASA Physical Status 2 A patient with mild systemic disease 
ASA Physical Status 3 A patient with severe systemic disease 
ASA Physical Status 4  
A patient with severe systemic disease that 
is a constant threat to life 
ASA Physical Status 5  
A moribund patient who is not expected to 
survive without the operation 
ASA Physical Status 6 
A declared brain-dead patient whose 
organs are being removed for donor 
purposes 
ASA E 
Emergency operation of any variety (used 
to modify one of the above classifications, 
i.e., ASA-4E) 
Table 2. ASA Physical Status classifications from the American Society of Anesthesiologists 
3. Perioperative risk 
The patient with pulmonary hypertension (PHTN) is at elevated risk for morbidity and 
mortality in the perioperative period [Cuenco et al, 1999; Kuralay et al, 2002; Tay et al, 1999; 
Rodriguez et al 1998]. There is a relative paucity of literature studying outcomes in this 
population presenting for noncardiac surgery, however, the evidence that does exist points 
to significantly increased potential for complications in the perioperative period. 
Ramakrishna et al. presented the results from an overview of 145 patients with PHTN 
presenting for noncardiac surgery. A 42% rate of early (<30 days) morbidity and a 9.7% rate 
of early mortality in this population have been reported. [Ramakrishna et al, 2005] Clinical 
characteristics associated with early morbidity and mortality are shown in Table 3.  
 
Table 3. Clinical characteristics associtated with increased morbility and mortality in PHTN 
patients. (Ramakrishna et al, 2005)  NYHA = New York Heart Association, RVSP = right 
ventricular systolic pressure, SBP = systolic blood pressure. 
Lai et al. performed a case-control study examining using 67 cases of patients with pulmonary 
systolic pressures greater than 70 mm Hg compared to controls with normal pulmonary 
pressures. [Lai et al, 2007]  As shown in table 4, the pulmonary hypertension group 
demonstrated greater postoperative heart failure (9.7 vs. 0%, p = .028), delayed tracheal 
extubation (21 vs. 0%, p = .004) and greater in hospital mortality (9.7 vs. 0%, p = .004).  
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A review of a large U.S. database by Memtsoudis et al. was undertaken to identify mortality in 
patients undergoing total hip arthroplasty (THA) and total knee arthroplasty 
(TKA).[Memtsoudis et al., 2010]  The authors identified 1359 THA and 2184 TKA patients that 
also carried the diagnosis of pulmonary hypertension. In comparison to a matched sample 
without pulmonary hypertension, the THA patients demonstrated a 4-fold increased adjusted 
risk of in-hospital mortality and the TKA patients demonstrated a 4.5-fold increase (p< .001). 
 
Table 4. Postoperative morbidity in patients with Pulmonary Hypertension compared to 
controls. (Lai et al., 2007)  PH= Pulmonary Hypertension (Pulm Syst. BP >70mm Hg) 
In summary, patients with PHTN are at considerably increased risk in the perioperative 
period morbidity and mortality. 
4. Intraoperative considerations 
The right ventricle (RV) is a crescent shaped, thin walled, compliant muscle intended for 
volume work, not pressure work. Chronic PHTN leads to right ventricular hypertrophy as a 
compensatory mechanism. However, the ability of the RV to adapt is finite and may 
eventually lead to RV failure. Unlike the muscular left ventricle, a hypertrophied RV may 
not tolerate the acute rises in PVR that are associated with pain, surgical stimulation and 
positive pressure ventilation. RV failure and dilatation can lead to left ventricular 
compression and diminished cardiac output. This in turn leads to decreased coronary blood 
flow and perfusion pressure and can become a viscous cycle that can be difficult to 
overcome. The goals of management are to optimize PAP’s, RV preload and to avoid RV 
ischemia and failure. During anesthesia and surgery, there are significant alterations in all 
the above parameters and appropriate vigilance and monitoring is essential. Proper 
operating room monitoring for patients with pulmonary hypertension usually involves 
placement of arterial and/or pulmonary artery catheters and/or a transesophageal 
echocardiography probe. Intra-arterial blood pressure monitoring is necessary for beat-to-
beat blood pressure monitoring to ensure adequate myocardial perfusion pressures and for 
frequent blood gas analysis. A pulmonary artery catheter can be used in addition to PCWP 
to give an indication of left ventricular preload in the patient with PHTN whose cardiac 
output is limited by right ventricular function. Central venous pressure may be a more 
accurate guide for volume administration. Additionally, PVR, SVR, and cardiac outputs can 
be measured and used as guides for volume, vasodilator, or inotropic therapy. Care should 
be taken in placing these catheters as these patients are reliant on atrial contraction for 
adequate preload and cardiac output. Arrhythmias associated with catheter insertion may 
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not be tolerated well by the patient. Finally, transesophageal echocardiography can be 
useful to assess the preload and contractility of both right and left ventricles. 
4.1 Echocardiography and pulmonary hypertension 
Echocardiography can be useful for both diagnosis and monitoring of disease progression in 
pulmonary hypertension (PH). Although transthoracic echocardiography is most widely 
used for this purpose, transesophageal echocardiography (TEE) can be useful for patients 
with poor acoustic windows and for intraoperative monitoring. Compared to other 
monitoring modalities, TEE can be particularly useful in narrowing the differential for 
intraoperative hemodynamic instability (hypovolemia, hypervolemia, right or left 
ventricular ischemia/failure) and in formulating a therapeutic plan. 
Multiple echocardiographic methods, M-mode, 2D and real-time 3D have been utilized to 
assess PH. The echocardiographic findings associated with PH include:  (i) a diminished or 
absent atrial wave of the pulmonary valve, (ii) mid-systolic closure or notching of the 
pulmonary valve,  (iii) enlarged right atrial or right ventricular (RV) chambers, (iv) 
intraventricular septal flattening, (v) paradoxical systolic motion of the intraventricular 
septum (IVS) toward the left ventricle, (vi) a dilated inferior vena cava with reduced 
respiratory variability, (vii) increased IVS/posterior left ventricular (LV) wall ratio (>1), 
(viii) increased RV end-diastolic volume index, (ix) increased RV end-systolic volume index, 
and (x)decreased RV ejection fraction.[Bossone et al, 2005; Mookadam et al., 2010; Morikawa 
et al., 2011]   Methods to determine pulmonary arterial pressure include:  measurement of 
the tricuspid annular plane systolic excursion (TAPSE), two-dimensional strain, tissue 
Doppler echocardiography, the speckle tracking method, acceleration time across the 
pulmonic valve, the pulmonary artery regurgitant jet method and the tricuspid regurgitant 
jet method. (Janda et al, 2011) The tricuspid regurgitant jet method is the most commonly 
used for determination of the pulmonary artery systolic pressure (PASP). The simplified 
Bernoulli equation, P1 – P2 = 4V2 , where P1 – P2  is the pressure gradient and V is the peak 
velocity,  is used to approximate the PASP  by continuous wave Doppler across the 
tricuspid valve regurgitant jet. In this case, RVSP ≈ PASP = 4V2 + RAP, where RVSP is the 
right ventricular systolic pressure and RAP is the right atrial pressure. The RVSP 
approximates PASP when no pulmonary valve stenosis or right ventricular outflow 
obstruction exists. [Janda et al., 2011; Sciomer et al., 2011]  Figure 1 demonstrates the 
enlarged right ventricle, deviated intraventricular septum and compressed left ventricle. 
Although right heart catheterization (RHC) remains the gold standard for assessment of 
hemodynamics in PH, advantages of echocardiography include wide availability, 
noninvasive modality, and costs. Intraoperatively, TEE allows dynamic interpretation and 
assessment of the therapeutic management of PH. Disadvantages include the need for 
specialized training for interpretation, modest diagnostic accuracy and correlation to PH as 
compared to RHC.[ Fisher et al., 2009; Janda et al., 2011]  Janda et al found the summary 
correlation coefficient of systolic pulmonary artery pressure (PASP) by echocardiography as 
compared with PASP by RHC to be 0.70 (95% CI 0.67 to 0.73) as well as a summary 
sensitivity and specificity of 83% (95% CI 73 to 90) and 72% (95% CI 53 to 85), respectively 
for diagnostic accuracy of echocardiography for pulmonary hypertension. (Janda et al, 2011)  
The variability of echocardiography to correlate to RHC is in part due to the underlying 
disease, lung conditions, time of the examination, and the skills of the echocardiographer. 
www.intechopen.com
 
Perioperative Management of Pulmonary Hypertension 
 
281 
[Mookadam et al, 2010; Pedoto & Amar, 2009; Sciomer et al., 2007]  Underestimation of 
PASP by echocardiography resulting in improper classification of PH (mild, moderate, 
severe) is more likely than overestimation, however inaccuracy in both under and 
overestimation occur with similar frequency. [Fisher et al., 2009]  Improvement in obtaining 
the tricuspid regurgitant jet peak velocity has been found with the use of an intravenous 
bolus of agitated saline. [Bossone et al., 2005; McLaughlin et al., 2009; Mookadam et al, 2010]  
Despite the technical challenges and inaccuracies associated with echocardiography, it 
remains as useful tool for the diagnosis, monitoring, and management of PH. 
 
Fig. 1. Top: Apical four-chamber view (systole) showing enlarged right-side chambers with 
compressed and geometric distortion of an intrinsically normal LV secondary to marked RV 
pressure overload; severe TR. RA-right atrium; LA- left atrium. Bottom: Peak TR velocity of 
4.68 m/s, with a peak gradient of 87.8 mm Hg indicating severe PH. (Bossone et al., 2005) 
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4.2 Anesthetic technique and pharmacological considerations 
Outside of case reports, very little literature exists evaluating management strategies for 
intraoperative and postoperative management of the patient with pulmonary hypertension. 
Various management techniques have been described with success including regional, 
general, and peripheral nerve blockade. [Armstrong, 1992; Martin et al., 2002]  The choice of 
technique is not as important as the ability to adhere to the goals of avoidance of elevations 
in PVR and right ventricular failure.  
4.2.1 Regional anesthesia 
Regional techniques, including peripheral nerve blockade and neuraxial blockade (epidural, 
spinal anesthesia) have been successfully utilized in patients with severe pulmonary 
hypertension. Among the benefits are avoidance of the stimulation of direct laryngoscopy 
and endotracheal intubation. Even with adequate IV hypnotics, opioids and neuromuscular 
blockade, it is difficult to avoid increases in sympathetic nervous system activity with direct 
laryngoscopy. These increases could lead to increases in PVR and potential acute right heart 
failure. Additionally, during a general anesthetic, with the variable stimulation during the 
operative procedure, the anesthesiologist is continually managing the balance between 
excessive sympathetic outflow, increased PVR and potential acute right heart failure on one 
hand and excessive depth of anesthesia, low cardiac output, low coronary perfusion and 
cardiovascular collapse on the other hand. (Hohn L et al., 1999)  The healthy patient 
tolerates these variations well, but the patient with severe PH has limited reserve to tolerate 
acute increases in PVR or decreased coronary perfusion. A peripheral nerve block technique 
can limit anesthesia to the specific location of the surgery and avoid the need for the 
stimulation of intubation and reduced likelihood of sympathectomy and low blood pressure 
as one would achieve with general anesthesia. An important distinction is that a 
sympathectomy is still possible when utilizing a regional anesthesia technique such as 
epidural or spinal anesthesia. This may lead to arterial and venous dilation and reduced 
preload and cardiac output compromising coronary perfusion.  
When utilizing regional or peripheral techniques, it is important to ensure adequate 
ventilation and oxygenation to prevent increases in PVR. For example, sedation provided to 
allow the patient to tolerate placement of a peripheral nerve block or to tolerate laying on 
the narrow, stiff operating table may lead to hypoxemia and hypercarbia secondary to 
hypoventilation. On the other hand, lack of sedation can promote anxiety, pain and 
sympathetic stimulation. Finding the appropriate balance can be a challenge for the 
anesthesiologist.  
4.2.2 General anesthesia 
For major surgery, general anesthesia is still the method of choice and allows for control of 
ventilation. Commonly used intravenous anesthetics such as propofol and thiopental are 
associated with hypotension and some myocardial depression. Their use should be 
judicious. Etomidate has much less an effect on SVR, PVR and myocardial contractility and 
may be a more useful hypnotic for patient with severe pulmonary hypertension. Use of 
volatile anesthetics is associated with decreased SVR, myocardial contractility and potential 
arrhythmias all of which can impair right ventricular myocardial perfusion and also right 
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ventricular cardiac output. A balanced technique utilizing high dose narcotics to blunt the 
cardiovascular response to surgical stimulation and minimal volatile anesthetics can limit 
these adverse effects. Additionally, the anesthesiologist should strive to use basic 
physiology to his advantage. These principles include utilization of 100% oxygen for its 
pulmonary vasodilator effects, and aggressive treatment of hypercarbia, acidosis, and 
hypothermia as these all cause pulmonary vasoconstriction. Certain anesthetic agents such 
as nitrous oxide and ketamine have been associated with increases in PVR and should be 
used with caution [Rich et al., 1994; Schulte-Sasse et al., 1982].  
Intraoperative management of the right ventricle can be made on the presence of RV failure 
and the presence of systemic hyper- or hypotension. Initially, one should ensure that 
oxygenation, ventilation, and acid/base status are optimized. Treatment options for PHTN 
include both intravenous (IV) and inhaled agents. Intravenous vasodilators, such as 
nitroglycerin, sodium nitroprusside, beta blockers, calcium channel blockers, and certain 
prostaglandin preparations will cause dilation of both the pulmonary and systemic vascular 
beds and can be useful in the setting of PHTN with systemic hypertension. The advantages 
to IV preparations are the relative decreased cost, easier availability of medications, longer 
duration of action and ease of administration in comparison to inhaled agents. 
Milrinone is a phosphodiesterase-3 inhibitor and prevents the breakdown of cyclic 
adenosine monophosphate (cAMP). It has shown to reduce both PVR and SVR in addition 
to causing increases in myocardial contractility [Tanake et al, 1991]. If the clinical picture is 
of pulmonary hypertension with systemic hypotension, IV vasodilators may cause 
worsening of systemic blood pressure, subsequent RV hypoperfusion, ischemia and failure. 
In this situation, the patient may benefit from therapy selective for the pulmonary 
vasculature such as inhaled nitric oxide (INO) or prostacyclin. 
INO diffuses from the alveoli to the pulmonary capillaries and acts via stimulation of 
guanylate cyclase and increasing cyclic guanosine monophosphate (cGMP) leading to 
vasodilation. INO does not produce systemic vasodilatation because nitric oxide is 
inactivated when bound to hemoglobin. It also has the benefit of improving ventilation–
perfusion matching by increasing perfusion to areas of the lung that are well ventilated. 
INO has been shown to improve PHTN in cardiopulmonary bypass settings [Ichinose et al., 
2004; Kavanaugh & Pearl, 1995]. Prostacyclin, available in inhaled and i.v. forms, stimulates 
adenylate cyclase and increases cAMP and release of endothelial NO leading to decreases in 
PAP, right atrial pressures, and increased cardiac output. An example of a prostacyclin 
nebulized delivery system that can be integrated into the anesthesia circuit is shown in 
Figure 2. [Jerath, 2010]  Combination therapy, with both INO and prostacyclin, has been 
shown to augment the effects compared to monotherapy [Atz et al., 2002; Petros et al., 1995]. 
Due to the extremely short half-life of these medications, one should ensure that the 
medication is delivered continuously without interruption to minimize the risk of rebound 
pulmonary hypertension. Weaning from these medications should be performed gradually 
with frequent assessment of pulmonary artery pressures and the right ventricle. A 
disadvantage of INO compared to inhaled prostacyclin is its cost. A recent analysis revealed 
that INO is approximately 20 times more expensive than prostacyclin ($3000/day vs. 
$150/day). [De Wet, 2006]. Table 5 lists the medical management options, including 
common doses, for intraoperative pulmonary hypertension. Lastly, in patients refractory to 
the above therapies, right ventricular assist device implantation should be considered. 
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1. Ensure good oxygenation, avoid hypercarbia, acidosis and hypothermia 
2. Inhaled nitric oxide 20–40 ppm. 
3. Milrinone (phosphodiesterase III inhibitor) is 50mcg/kg bolus, then 0.5–0.75mcgkg-1min-1 
4. Dipiridamole is 0.2–0.6 mg/kg i.v. over 15 min. Repeat after 12 h. 
5. Inhaled prostacyclin: Continuous administration of 50 ngkg-1min-1. Reconstitute 
prostacyclin in sterile glycine diluent to 30,000 ng/ml (1.5mg of prostacyclin in 50 ml of 
diluent). For an 80 kg patient, 50 ng/kg per min is 8 ml of this solution per hour. It is 
nebulized into inspiratory limb (see Figure 2).  
6. Intravenous prostacyclin (if inhaled is not available) is 4–10 ngkg-1min-1. 
7. Wean the above medications slowly to prevent rebound pulmonary hypertension. 
8.  Regional anesthesia can be provided using peripheral nerve blockade, brachial plexus 
block, and lumbar plexus block. 
9.  Epidural anesthesia should be induced slowly. Mixtures of local anesthetics and 
opioids should be given to reduce the dose of local anesthetics and hypotension. 
10. Hypotension should be treated according to causes. Phenylephrine and norepinephrine 
have been used to treat persistent systemic hypotension. Norepinephrine has the 
advantage of being both a vasoconstrictor and positive inotropic agent. In hypotension, 
dobutamine and vasopressin have also been advocated for treatment of hypotension 
[Pearl, 2005; Subramaniam & Yared 2007].  
Table 5. Management options for intraoperative PHTN (modified from Blaise et al., 2003). 
 
 
Fig. 2. Inhaled prostacyclin delivery system. Reconstituted prostacyclin is delivered by a  
Lo-Flo MiniHeart nebulizer (a), which is driven by a separate oxygen source at 2 L/min (b). 
The nebulizer output is 8 mL/h, which allows for 1–3 h of continuous nebulization.  
The nebulizer should be supported by an IV pole or ventilator side arm to prevent spillage. 
An IV port (c) allows the chamber to be refilled without disconnecting from the anesthetic 
circuit. Prostacyclin is photosensitive and requires the nebulizing chamber to be covered 
from ambient light (d). [Jerath, 2010] 
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5. Postoperative management 
These patients warrant intensive care monitoring in the postoperative period with 
experienced critical care personnel. As the analgesic and sympathetic nervous system effects 
of opioids, volatile anesthetics, and regional anesthetics, the patient can develop sudden 
worsening of PHTN and RV ischemia. Weaning from the ventilator and extubation should 
be done gradually with close attention to adequate oxygenation, ventilation and analgesia. 
Even routine events such as bucking on the ventilator due to tracheal stimulation, while 
tolerated in the average patient, can lead to acute rises in PVR and RV failure in the patient 
with severe PHTN [Rodriguez & Pearl, 1998]. 
6. Conclusion 
Due to advances in the management of PHTN, it appears likely that these patients will be 
encountered more frequently in the perioperative period for procedures incidental to their 
primary disease process. These patients present challenging clinically scenarios secondary to 
the complexity of their PHTN and are at increased risk for significant perioperative 
complications. The ideal perioperative care of these patients requires a multidisciplinary 
approach with appropriate planning for pre-procedure optimization, appropriate resources 
and monitoring intra-operatively as well as intensive care unit monitoring in the post-
operative period. This aggressive approach can test the expertise and resources of medical 
institutions. Although no curative agent has been identified, the practitioners’ knowledge of 
the existing treatment options, pathophysiology, and the implications of various anesthetic 
agents and techniques are required to ensure the highest level of patient safety and care. 
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